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doi:10.1Objective:Malpositioning is one of the major problems in transcatheter aortic valve implantation. To evaluate
the influence of mechanical balloon inflation on aortic valve stent positioning, the expansion process and the
impact on the valve leaflet’s structure were investigated.
Methods: Custom-made stents were laser cut from a 22-mm diameter stainless steel tube and mounted with
a glutaraldehyde-treated bovine pericardial valve. The valved stents were crimped onto a standard balloon cath-
eter and expanded by inflation of the balloon with 2 bar for 3 seconds. Expansion was studied using a high-speed
camera, and the histology of the pericardial tissue was analyzed.
Results: The valved stents were fully expanded within 3 seconds. Balloon inflation was observed to be asym-
metric starting proximally. At the beginning of expansion, the valved stents were pulled proximally. During
further inflation, the stents slipped distally on the balloon and experienced a total displacement of 13.5 mm.
Macroscopic examination showed severe imprinting of the stent struts into the pericardial tissue. Histology
revealed disrupted tissue layers and collagen fibers.
Conclusions:Analysis of valved stent expansion showed a displacement of the stent on the catheter during balloon
inflation. Therefore, precise placement of the valved stent cannot be accomplished. Histologic analysis of the
expanded pericardial tissue revealed disruption of collagen fibers. Disruption of pericardial tissue structures due
to balloon expansion may result in early functional valve failure. (J Thorac Cardiovasc Surg 2012;143:1417-21)Video clip is available online.
Two catheter-based aortic valve prostheses are currently
available in Europe for transcatheter aortic valve implanta-
tion (TAVI): the Edwards SAPIEN Aortic Bioprosthesis
(Edwards Lifesciences LLC, Irvine, Calif) and the Med-
tronic CoreValve System (Medtronic Inc, Minneapolis,
Minn). The SAPIEN bioprosthesis consists of a stent
made of a cobalt chromium alloy with glutaraldehyde-
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Sstent is crimped onto the balloon catheter just before im-
plantation using a ‘‘crimper.’’ The stent is expanded and
placed by expanding the balloon inside of the valved stent.
In contrast, the CoreValve System uses a self-expanding
stent made of Nitinol memory metal with glutaraldehyde-
treated porcine pericardial leaflets. The Nitinol stent is
crimped to a small diameter in ice water and pushed into
the catheter sleeve just before implantation. When retract-
ing the sleeve, the Nitinol stent expands and self-anchors
in the aortic root.1 We investigated the behavior of a cus-
tom-made, steel, balloon-expandable valved stent during
the process of balloon expansion.
For more than 20 years, it has been well known that me-
chanical stress and disruption of collagen fiber structure in
prosthetic valves leaflets initiate calcification of the leaflet
tissue and cause early valve deterioration.2 Functional
and mechanical stress factors are assumed to contribute to
calcification.3-5
In 1990, Thubrikar6 summarized the effects of stresses
on biological tissues used as heart valve prostheses. Stress
in pericardial tissue causes delamination of the tissue
layer and disruption of collage fiber structure, both of
which result in leaflet calcification and early valve
deterioration.
The pericardial tissue used in catheter-based valve pros-
theses undergoes compression when the stent is crimped
onto the deflated balloon and then again undergoes com-
pression and high stress when the stent is expanded withdiovascular Surgery c Volume 143, Number 6 1417
Abbreviation and Acronym
TAVI ¼ transcatheter aortic valve implantation
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Sthe high-pressure balloon.We investigated the possibility of
impairment of the fragile pericardial tissue during this
process.FIGURE 2. Expanded stents (A, stent 1; B, stent 2) during balloon infla-
tion with 2 bar for 3 seconds.MATERIALS AND METHODS
Stent
Custom-made stents with 2 different closed-cell designs were laser cut
from a 22-mm diameter stainless-steel tube bearing a wall thickness of
0.5 mm and a height of 16 mm. One stent design included only a diamond
shape (Figure 1, A), and one stent design included vertical struts
(Figure 1, B). To ensure an even surface, the stents were polished after
the laser cutting process.
Pericardium
Calf pericardium was harvested at a public abattoir, where it was stored
in cold water (4C) and immediately transferred to the laboratory. Careful
cleaning was performed to not disrupt the pericardial structure with instru-
ments. The pericardium was then carved to produce a tension-free, flat,
0.7- to 0.8-mm–thick specimen that was placed in a flat basin at room tem-
perature and treated with 0.65% buffered glutaraldehyde for 7 days. The
pericardium was trimmed into rectangular strips according to the height
and circumferential distance of the stent used (stent 1 was 70 3 20 mm).
Ten pericardial strips were then mounted in the stents: 5 strips in each stent
design (Figure 1, A and B).
Balloon
The valved stent was crimped onto a standard balloon catheter (25.0
mm, NuCLEUS; NuMED, Inc, Hopkinton, NY). For expansion, the bal-
loon was inflated with a 50-mL, saline-filled syringe using the standard pro-
cedure for in vivo TAVI. The balloon was dilated with a maximum pressure
of pmax ¼ 2 bar within 1 second, and the pressure was held for 3 seconds
(Figure 2). The entire expansion procedure was digitally recorded with
a high-speed camera (HCC 1000; VDS, Osnabr€uck, Germany) using Im-
ageJ software.7 In our captured images, the software’s pixel length ofFIGURE 1. A, Stent 1: stainless-steel stent with diamond-shaped cells and bovi
struts and bovine pericardium attached.
1418 The Journal of Thoracic and Cardiovascular Sur14.5 mm corresponding to 295 pixels was calibrated on the basis of the
lengths of the stent strut and the stitch holes.
Histology
Immediately after the expansion procedure, the pericardium was un-
coiled from the stents and macroscopically analyzed. For histologic exam-
ination, the specimens were preserved in 10% phosphate-buffered
formalin for 2 days, processed and embedded in a conventional tissue pro-
cessor (Shandon Pathcentre; Thermo Scientific, Dreieich, Germany),
where they underwent dehydration through serial bath treatments contain-
ing xylol and ethanol, and finally embedded in paraffin. The formalin-fixed,
paraffin-embedded tissue was cut into 4-mm–thick slices using a rotary mi-
crotome (Leica RM2135; Leica Microsystems GmbH, Wetzlar, Germany)
in longitudinal sections through the pericardial conduit, longitudinalne pericardium attached. B, Stent 2: stainless-steel stent with 3 commissural
gery c June 2012
FIGURE 3. The image sequence shows the sliding movement of valved
stent number 2 during its expansion: A, The starting position of the stent
is line A; B, During inflation, the stent migrated 4.5 mm in the proximal
direction to line B; C, At the end of balloon dilation, the direction switched,
and the valved stent slid to the distal position (line C) with a maximum dis-
placement of 13.5 mm. A slow-motion video of the camera sequence that
ends on this frame can be seen in Video 1.
FIGURE 4. A, Native pericardium trimmed into a rectangular strip before
being sutured into the stent. B, Unrolled pericardium after stent 1 expan-
sion with a pressure of 2 bar for 3 seconds. C, Unrolled pericardium after
stent 2 expansion with a pressure of 2 bar for 3 seconds. Note the imprinted
shape of both stents onto the pericardium, like a ‘‘skid mark.’’
de Buhr et al Evolving Technology/Basic Sciencesections through the middle of each cusp, and a transverse section through
each commissure. Representative sections were stained with Elastica-van
Gieson (Resorcin-Fuchsin) for collagen morphology.E
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Expansion
To present the main focus of attention during expansion,
a selection of high-speed images is shown (Figure 3;
Video 1). The expansion procedure was divided into 2 pe-
riods: (1) At the beginning of expansion, only the proximal
part of the balloon inflated, because the crimped stent pre-
vented the injected fluid from flowing freely to the distal
part of the balloon. This asymmetric balloon expansion
proximally displaced the valved stent (Figure 3, distance
A to B). (2) After the proximal part of the balloon was fully
inflated, the expanding balloon pushed the valved stent dis-
tally, and the valved stent slid to the distal end of theThe Journal of Thoracic and Carcatheter (Figure 3, distance B to C). Both valved stents
were expanded within 1 second with a pressure of 2 bar,
and the pressure was held for 3 seconds. For the displace-
ment, we measured a maximum value of 4.5  0.1 mm be-
tween line A and B and 13.5  0.1 mm between B and C.
Pericardium
During stent expansion by balloon inflation with a pres-
sure of 2 bar, the pericardium was pressed against the stent
struts for 3 seconds. Macroscopic analysis showed that
compression of the pericardium against the stent structure
resulted in an imprinted ‘‘skid mark’’ (Figure 4).
Histology
Elastica-van Gieson staining was used to visualize the
general collagen morphology of the pericardium. In all 10
histologic samples (n ¼ 5 of Figure 1, A and n ¼ 5 of
Figure 1, B), broken collagen fibers were observed at 2
levels: The tissue surface was disrupted and the superficial
collagen fibers were broken at the corner of the stent-strut
indent, and collagen fibers were disrupted at the edge of
the indent along an oblique line into deeper situated layers
(Figure 5). No differences were observed between the 2
groups (Figure 1, A and B).
DISCUSSION
Correct valve positioning is crucial for successful TAVI,
but as Kapadia and Tuzcu8 stated in 2009, major complica-
tions of TAVI include device malpositioning. Optimal an-
giographic projection of the aortic annulus is essential for
accurate TAVI positioning.9 Nevertheless, the accuracy ofdiovascular Surgery c Volume 143, Number 6 1419
FIGURE 5. A, Histology of the pericardium indented by the stent’s struts. B, Histology of the boxed area from A (X ¼ disrupted surface and broken
superficial collagen fibers; Y ¼ broken collagen fibers in the deeper layers of the pericardial leaflet).
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2009, Jilaihawi and coworkers10 described optimal posi-
tioning in 50% of their cases, whereas Zajarias and Crib-
ier11 reported tolerable placement in 92.8% of their cases.
However, remaining paravalvular leakage in more than
50% of the implantations due to suboptimal positioning
has also been reported.12 Placement of a second valve
(valve-in-valve) is required in up to 3% of cases to correct
a prior valve malposition.13
Our results show that the skill of the implantation team
is not the only relevant factor in correct valved stent po-
sitioning. Another factor (revealed by high-speed cam-
era) that should be taken into consideration is the
displacement of the valve caused by asymmetric balloon
expansion. The asymmetric nature of the expansion of
the stented valve on the balloon leads to displacement
of the valved stent on the catheter. This acute migration
of the valved stent impedes precise positioning of the
valve.
The TAVI valve prosthesis is crimped onto the balloon
right before it is implanted.14 For valve deployment, the de-
livery balloon is inflated to expand the valved stent, thereby
compressing the native aortic valve against the stent
structure.
Histologic examination of the expanded pericardial tis-
sue revealed strut imprints on the valve tissue with disrupted
leaflet surface structures and broken collagen fibers. The
disruption of the leaflet surface structures is expected to
lead to a higher risk of early valve thrombosis.15,16 In
pericardial bioprostheses, calcification is found along the
shear planes where the structural integrity has been
disrupted by individual layers of collagen sliding over
each other and where mechanical stresses damaged the
structural integrity of the leaflet tissue.2
The damage of tissue structures caused by balloon expan-
sion that was obvious in our experiment is expected to cause
early leaflet calcification, resulting in early functional valve
failure.
Zegdi and colleagues17 recently published a clinical
study that revealed traumatic injury to leaflets after percuta-
neous valve implantation. Our study confirms these findings1420 The Journal of Thoracic and Cardiovascular Surand demonstrates a possible cause for the observed pericar-
dial leaflet injury.
Study Limitations
The custom-made stents in this experiment are not fully
comparable to the commercially available stents used for
valve implantation. The stents used in this experiment
were made of stainless steel, whereas the commercially
available balloon expandable stents are made of cobalt
chromium alloy (Edwards SAPIEN Aortic Bioprosthesis)
and Nitinol (Medtronic CoreValve). The material properties
surely differ and were not investigated in this study. There-
fore, our results cannot be directly applied to the commer-
cially available devices. In addition, the valve leaflet
design in our custom-made stents was a simple strip of peri-
cardium and differs from the valve design in the commer-
cially available prostheses.
We did not investigate or differentiate whether the crimp-
ing alone or the expansion process alone caused injury to
the pericardial leaflets.
The in vitro experimental model we used differs from
a real clinical scenario. When the valve frame is balloon ex-
panded in a stenotic and calcified aortic root, the stent has
a large contact area with the native valve leaflets, and this
may reduce the described effect of stent displacement
caused by the asymmetric balloon dilation.
Finally, this study was not intended to investigate the
long-term effects of the observed leaflet injury.
CONCLUSIONS
Analysis of valved stent expansion showed asymmetric
balloon inflation, which displaces the stent during expan-
sion. This movement prevents precise placement of
balloon-expandable valved stents. Histologic analysis of
expanded pericardial tissue revealed strut imprints on the
valve tissue, disruption to the surface of the tissue, and
disrupted collagen fibers. Disruption of tissue structures
due to balloon expansion may result in early functional
valve deterioration. Further investigation regarding the clin-
ical relevance of the observed tissue injury is essentially
mandatory.gery c June 2012
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